Hong Kong is George Clinical’s East Asia hub, overseeing our operations in Taiwan and Malaysia.
Hong Kong is George Clinical’s East Asia hub, overseeing our operations in Malaysia, Singapore, South Korea, Taiwan, Thailand, Philippines, Indonesia and Vietnam
Hong Kong has a long history of international research with sophisticated infrastructure and resources across all phases. A small, densely populated area, Hong Kong’s world class hospitals offer excellent recruitment potential. Hong Kong has a long and impressive track record of conducting global clinical trials. Since the introduction of ICH GCP in 1996, Hong Kong has participated in over 1000 global clinical trials. Hong Kong has had a history of high quality clinical research output and plays a role of scientific leadership in Asia.
Hong Kong has excellent infrastructure in terms of transportation, work force and legal framework. Hong Kong has an outstanding healthcare system, as indicated by one of the lowest infant mortality rates and the longest life expectancy in the world. There are 42 public hospitals which provide 90% of the medical care in Hong Kong.
Hong Kong is officially recognized by China State Food and Drug Administration for conducting clinical trials for drug registration purpose in mainland China in certain therapeutic areas. There is strong government support in clinical research, with the recent example being the set up of two Phase I centres at leading teaching hospitals in Hong Kong.
Clinical trial data from Hong Kong can be used to file new drug applications, making Hong Kong a gateway to the mainland China.
Central Nervous System 33%
Medical Devices 22%
|Official Language||Chinese (Traditional Chinese), English|
|Hospital Records Language||English|
|Electronic Hospital Records||Yes, stored centrally|
|Site Network||42 public hospitals, which provide 90% of medical care in Hong Kong|
|In-country services||Project Management
|GDP – per capita (US $)||$64,533|
My name is Evon Hui and I am the Associate Business Director of Business Operations in East Asia
Currently, we have entities in East Asia across four countries, the hub is in Hong Kong and we have offices in Taiwan, South Korea, Malaysia. But we do have cover of clinical trials in different regions apart from these four countries and they are: Thailand; Vietnam; Singapore; and, Philippines. In terms of the populations, it’s estimated to be around 640 million people in these regions and definitely this provides a very large number of patient pools for conducting clinical trials.
Just to mention again, it’s a wide population with wide diversity that offers a wide genetic diversity of population and on top of that, it offers a relatively lower cost comparing to the western countries like in Europe or in the US, it’s relatively more cost effective; and on top of that there are increasing number of enthusiastic researchers, very developed infrastructures in the hospitals that’s very good for conducting clinical trials.
We had started our operations back in 2009 and we offer various services that includes: project management; clinical operations; clinical monitoring; safety; and compliance. We have about six to ten personnel in each location that includes South Korea, Taiwan, Malaysia and Hong Kong. So total around 30 to 35 people on the ground.
In East Asia, we do offer a wide variety of services, wide range of services – includes: project management; clinical monitoring; safety reporting; as well as, compliance.
Whenever we receive a request for proposals, we would be evaluating the protocol together with our internal team. We might be conducting a high-level feasibility through our networks, through our scientific leaders, getting their opinions, which are the good sites and what’s the prevalence in each country and that way we would be proposing to our sponsors, this is the geomix that we think would be great for your study. And of course, we would be having a very tight communication with the sponsors and helping them to decide which countries would be the best for their studies and of course at the end it would be the sponsor’s call or decision to decide which countries would be best to conduct their study.
Please get in touch with us through www.georgeclinical.com for more information.